The objective of this clinical trial is to evaluate the antihypertensive efficacy and safety of BR1400-1, BR1400-2, BR1400-3, BR1400-4, and BR1400-5 with essential hypertension.
For patients not currently receiving antihypertensive therapy: 140 mmHg ≤ MSSBP < 180 mmHg
For patients receiving antihypertensive therapy : 130 mmHg ≤ MSSBP < 180 mmHg
For patients without cardiovascular disease: 140 mmHg ≤ MSSBP < 180 mmHg
For patients with cardiovascular disease, diabetes with cardiovascular disease, albuminuria, or diabetes with chronic kidney disease (CKD): 130 mmHg ≤ MSSBP < 180 mmHg
Patients with blood pressure results showing MSSBP ≥ 180 mmHg or MSDBP ≥ 110 mmHg at screening(V1) and baseline(V2)
Patients with a history of secondary hypertension or suspected secondary hypertension; (e.g., coarctation of the aorta, hyperaldosteronism, renal artery stenosis, renal hypertension, pheochromocytoma, Cushing's syndrome and polycystic kidney disease, etc.)
Patients with shock
Patients with orthostatic hypotension accompanied by symptoms
6
Treatment groupsSee each treatment group below.